Although no evidence directly indicated the optimal NAC regimen in hormone receptor (HR)-positive/HER2-negative BC patients, NAC was suggested to be used instead of adjuvant chemotherapy, as patients treated with NAC had similar prognosis as those with adjuvant chemotherapy (5). The gene discussed is ERBB2; the disease is breast cancer.